VORANIGO
GrowthNDAORALTABLETPriority Review
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VORANIGO (vorasidenib) is an oral isocitrate dehydrogenase 1 (IDH1) inhibitor approved by the FDA on August 6, 2024. It targets IDH1-mutant malignancies by inhibiting the oncogenic enzyme and restoring normal cellular differentiation. This precision medicine approach addresses a genetically defined patient population with IDH1 mutations.
Growth12.2 years to LOE
Early-stage growth product with potential for rapid commercial expansion as real-world adoption establishes; team building and market development roles likely to increase.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VORANIGO represents a launch-phase precision oncology asset with a niche but high-value patient population, offering career momentum in specialized commercial, medical, and market access roles. Long patent protection and early lifecycle stage create medium-to-long-term career stability within an orphan/niche segment.
Brand ManagerMedical Science Liaison (MSL)
Worked on VORANIGO at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.